Panbela Therapeutics Unternehmenswert
Was ist das Unternehmenswert von Panbela Therapeutics?
Unternehmenswert von Panbela Therapeutics Inc. ist $9.68M
Was ist die Definition von Unternehmenswert?
Der Unternehmenswert ist ein Maß für den gesamten Marktwert eines Unternehmens. Es wird als Marktkapitalisierung mit Verschuldung, Minderheitsanteilen und Vorzugsaktien abzüglich der Zahlungsmittel und Zahlungsmitteläquivalente berechnet.
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Unternehmenswert von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Panbela Therapeutics
Was macht Panbela Therapeutics?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Unternehmen mit unternehmenswert ähnlich Panbela Therapeutics
- Makers Laboratories hat Unternehmenswert von $9.66M
- Mohit Industries hat Unternehmenswert von $9.67M
- Peppermint Innovation hat Unternehmenswert von $9.67M
- Invigor hat Unternehmenswert von $9.67M
- Curative Biosciences hat Unternehmenswert von $9.68M
- Surefire Resources NL hat Unternehmenswert von $9.68M
- Panbela Therapeutics hat Unternehmenswert von $9.68M
- Oakdale Resources hat Unternehmenswert von $9.69M
- Viva Gold hat Unternehmenswert von $9.69M
- Edensoft hat Unternehmenswert von $9.69M
- InnovaDerma Plc hat Unternehmenswert von $9.69M
- General Assembly hat Unternehmenswert von $9.70M
- Redbank Copper hat Unternehmenswert von $9.71M